Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Beijing Minhai Biotechnology Co Ltd Snapshot 7
Beijing Minhai Biotechnology Co Ltd Overview 7
Key Facts 7
Beijing Minhai Biotechnology Co Ltd - Research and Development Overview 8
Key Therapeutic Areas 8
Beijing Minhai Biotechnology Co Ltd - Pipeline Review 11
Pipeline Products by Stage of Development 11
Pipeline Products - Monotherapy 12
Pipeline Products - Combination Treatment Modalities 13
Pipeline Products - Partnered Products 14
Partnered Products/Combination Treatment Modalities 15
Beijing Minhai Biotechnology Co Ltd - Pipeline Products Glance 16
Beijing Minhai Biotechnology Co Ltd - Late Stage Pipeline Products 16
Pre-Registration Products/Combination Treatment Modalities 16
Phase III Products/Combination Treatment Modalities 17
Beijing Minhai Biotechnology Co Ltd - Clinical Stage Pipeline Products 18
Phase I Products/Combination Treatment Modalities 18
Beijing Minhai Biotechnology Co Ltd - Early Stage Pipeline Products 19
IND/CTA Filed Products/Combination Treatment Modalities 19
Preclinical Products/Combination Treatment Modalities 20
Beijing Minhai Biotechnology Co Ltd - Drug Profiles 21
(diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + polio + tetanus) vaccine - Drug Profile 21
Product Description 21
Mechanism Of Action 21
R&D Progress 21
(diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile 22
Product Description 22
Mechanism Of Action 22
R&D Progress 22
(hepatitis A + hepatitis B) vaccine - Drug Profile 23
Product Description 23
Mechanism Of Action 23
R&D Progress 23
(measles + rubella + varicella) vaccine - Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
cholera (trivalent) vaccine - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
Enterovirus [serotype EV-A71] vaccine - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
Haemophilus influenzae B vaccine - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
hepatitis A vaccine - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
hepatitis B vaccine - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
herpes simplex virus vaccine - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
herpes zoster vaccine - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
human papillomavirus (quadrivalent) vaccine - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
influenza (split virion) vaccine - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
influenza [strain A/H1N1] vaccine - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
influenza [strain A/H7N9] vaccine - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
meningococcal [serotype B] vaccine - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine 2 - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
mumps vaccine - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
pneumococcal (13-valent) vaccine - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
pneumococcal (23-valent) vaccine - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
rabies vaccine - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
rotavirus (pentavalent) vaccine - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
varicella zoster vaccine - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
Beijing Minhai Biotechnology Co Ltd - Pipeline Analysis 45
Beijing Minhai Biotechnology Co Ltd - Pipeline Products by Route of Administration 45
Beijing Minhai Biotechnology Co Ltd - Pipeline Products by Molecule Type 46
Beijing Minhai Biotechnology Co Ltd - Dormant Projects 47
Beijing Minhai Biotechnology Co Ltd - Locations And Subsidiaries 48
Head Office 48
Appendix 49
Methodology 49
Coverage 49
Secondary Research 49
Primary Research 49
Expert Panel Validation 49
Contact Us 49
Disclaimer 50

List of Tables
Beijing Minhai Biotechnology Co Ltd, Key Facts 7
Beijing Minhai Biotechnology Co Ltd - Pipeline by Indication, 2016 9
Beijing Minhai Biotechnology Co Ltd - Pipeline by Stage of Development, 2016 11
Beijing Minhai Biotechnology Co Ltd - Monotherapy Products in Pipeline, 2016 12
Beijing Minhai Biotechnology Co Ltd - Combination Treatment Modalities in Pipeline, 2016 13
Beijing Minhai Biotechnology Co Ltd - Partnered Products in Pipeline, 2016 14
Beijing Minhai Biotechnology Co Ltd - Partnered Products/ Combination Treatment Modalities, 2016 15
Beijing Minhai Biotechnology Co Ltd - Pre-Registration, 2016 16
Beijing Minhai Biotechnology Co Ltd - Phase III, 2016 17
Beijing Minhai Biotechnology Co Ltd - Phase I, 2016 18
Beijing Minhai Biotechnology Co Ltd - IND/CTA Filed, 2016 19
Beijing Minhai Biotechnology Co Ltd - Preclinical, 2016 20
Beijing Minhai Biotechnology Co Ltd - Pipeline by Route of Administration, 2016 45
Beijing Minhai Biotechnology Co Ltd - Pipeline by Molecule Type, 2016 46
Beijing Minhai Biotechnology Co Ltd - Dormant Developmental Projects,2016 47

List of Figures
Beijing Minhai Biotechnology Co Ltd - Pipeline by Top 10 Indication, 2016 9
Beijing Minhai Biotechnology Co Ltd - Pipeline by Stage of Development, 2016 11
Beijing Minhai Biotechnology Co Ltd - Monotherapy Products in Pipeline, 2016 12
Beijing Minhai Biotechnology Co Ltd - Combination Treatment Modalities in Pipeline, 2016 13
Beijing Minhai Biotechnology Co Ltd - Pipeline by Route of Administration, 2016 45
Beijing Minhai Biotechnology Co Ltd - Pipeline by Molecule Type, 2016 46